{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T14:04:43Z","timestamp":1791986683164,"version":"4.4.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Rheumatoid arthritis (RA) is associated with systemic bone loss and thus an established risk factor for osteoporosis. Janus kinase inhibitors (JAKi) have shown osteo-protective effects. However, clinical data on the effects of baricitinib on bone mineral density (BMD) remain limited. Therefore, we investigated the effects of a 1-year treatment with baricitinib on BMD in RA patients. Patients with active RA beginning treatment with baricitinib were included. BMD was measured at the lumbar spine and femoral neck using Dual-Energy X-Ray Absorptiometry (DXA). Disease activity was assessed using DAS28-CRP and cDAI. The primary endpoint was the change in BMD after 12\u00a0months. Secondary endpoints evaluated changes in disease activity, prednisolone dose and alkaline phosphatase (AP) levels and its relation to BMD. A total of 46 RA patients were recruited, of whom 26 completed the study. Overall, BMD remained stable. Non-responders to baricitinib (based on DAS28-CRP) showed a significant decline in spine BMD (\u2212\u20092.12%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.039), while responders showed stable BMD. The between-group difference in spine BMD (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.008) and T-score (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.012) was significant. Demographic and clinical characteristics did not differ significantly between groups. Disease activity (DAS28-CRP:\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.003; cDAI:\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.007), prednisolone dose (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.006), and AP levels (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.03) all improved significantly. Under baricitinib, BMD loss appeared stabilized in RA patients. Non-responders to baricitinib experienced a significant loss of BMD with a significant difference to responders raising the question if seen effects are achieved by controlling disease activity or if there is an additional explicit JAKi effect on bone metabolism. Trial registration number: DRKS00020780, date: 13.3.2020.\n                  <\/jats:p>","DOI":"10.1007\/s00223-025-01410-9","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T14:53:54Z","timestamp":1753196034000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Bone Mineral Density During Treatment with The Janus Kinase Inhibitor Baricitinib in Patients with Rheumatoid Arthritis: A Monocentric Observational Study"],"prefix":"10.1007","volume":"116","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-0378-3766","authenticated-orcid":false,"given":"Nils","family":"Schulz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1317-2138","authenticated-orcid":false,"given":"Thomas","family":"Asendorf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2629-1837","authenticated-orcid":false,"given":"Pascal","family":"van Wijnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-2400-2840","authenticated-orcid":false,"given":"Tim","family":"Wilhelmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8832-8112","authenticated-orcid":false,"given":"Ulf","family":"M\u00fcller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7904-0619","authenticated-orcid":false,"given":"Uwe","family":"Lange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7911-4235","authenticated-orcid":false,"given":"Philipp","family":"Klemm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1410_CR1","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s00393-022-01305-2","volume":"82","author":"K Albrecht","year":"2023","unstructured":"Albrecht K, Binder S, Minden K et al (2023) Systematisches Review zur Sch\u00e4tzung der Pr\u00e4valenz entz\u00fcndlich rheumatischer Erkrankungen in Deutschland. Z Rheumatol 82:727\u2013738. https:\/\/doi.org\/10.1007\/s00393-022-01305-2","journal-title":"Z Rheumatol"},{"key":"1410_CR2","doi-asserted-by":"publisher","first-page":"15844","DOI":"10.1038\/s41598-022-20016-x","volume":"12","author":"S Moshayedi","year":"2022","unstructured":"Moshayedi S, Tasorian B, Almasi-Hashiani A (2022) The prevalence of osteoporosis in rheumatoid arthritis patient: a systematic review and meta-analysis. Sci Rep 12:15844. https:\/\/doi.org\/10.1038\/s41598-022-20016-x","journal-title":"Sci Rep"},{"key":"1410_CR3","doi-asserted-by":"publisher","first-page":"275","DOI":"10.2147\/OARRR.S318810","volume":"13","author":"A Abdulkhaliq","year":"2021","unstructured":"Abdulkhaliq A, Cheikh M, Almuntashri F et al (2021) A comparison of demographics, disease activity, disability, and treatment among rheumatoid arthritis patients with and without osteoporosis. Open Access Rheumatol 13:275\u2013283. https:\/\/doi.org\/10.2147\/OARRR.S318810","journal-title":"Open Access Rheumatol"},{"key":"1410_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, Norton N, Harvey NC et al (2021) SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos 16:82. https:\/\/doi.org\/10.1007\/s11657-020-00871-9","journal-title":"Arch Osteoporos"},{"key":"1410_CR5","doi-asserted-by":"publisher","first-page":"ICT17","DOI":"10.7326\/AITC201708010","volume":"167","author":"KE Ensrud","year":"2017","unstructured":"Ensrud KE, Crandall CJ (2017) Osteoporosis. Ann Intern Med 167:ICT17. https:\/\/doi.org\/10.7326\/AITC201708010","journal-title":"Ann Intern Med"},{"key":"1410_CR6","doi-asserted-by":"publisher","first-page":"1287","DOI":"10.1007\/s00198-010-1192-7","volume":"21","author":"CJ Edwards","year":"2010","unstructured":"Edwards CJ, Williams E (2010) The role of interleukin-6 in rheumatoid arthritis-associated osteoporosis. Osteoporos Int 21:1287\u20131293. https:\/\/doi.org\/10.1007\/s00198-010-1192-7","journal-title":"Osteoporos Int"},{"key":"1410_CR7","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1007\/s11914-017-0358-z","volume":"15","author":"B Zhao","year":"2017","unstructured":"Zhao B (2017) TNF and bone remodeling. Curr Osteoporos Rep 15:126\u2013134. https:\/\/doi.org\/10.1007\/s11914-017-0358-z","journal-title":"Curr Osteoporos Rep"},{"key":"1410_CR8","doi-asserted-by":"publisher","first-page":"3336","DOI":"10.1002\/art.24920","volume":"60","author":"AD Bakker","year":"2009","unstructured":"Bakker AD, da Silva VC, Krishnan R et al (2009) Tumor necrosis factor \u03b1 and interleukin-1\u03b2 modulate calcium and nitric oxide signaling in mechanically stimulated osteocytes. Arthritis Rheum 60:3336\u20133345. https:\/\/doi.org\/10.1002\/art.24920","journal-title":"Arthritis Rheum"},{"key":"1410_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s00198-016-3769-2","volume":"28","author":"CAF Zerbini","year":"2017","unstructured":"Zerbini CAF, Clark P, Mendez-Sanchez L et al (2017) Biologic therapies and bone loss in rheumatoid arthritis. Osteoporos Int 28:429\u2013446. https:\/\/doi.org\/10.1007\/s00198-016-3769-2","journal-title":"Osteoporos Int"},{"key":"1410_CR10","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1007\/s00223-022-01001-y","volume":"111","author":"B Hauser","year":"2022","unstructured":"Hauser B, Raterman H, Ralston SH, Lems WF (2022) The effect of anti-rheumatic drugs on the skeleton. Calcif Tissue Int 111:445\u2013456. https:\/\/doi.org\/10.1007\/s00223-022-01001-y","journal-title":"Calcif Tissue Int"},{"key":"1410_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s41232-023-00293-3","volume":"43","author":"M Komagamine","year":"2023","unstructured":"Komagamine M, Komatsu N, Ling R et al (2023) Effect of JAK inhibitors on the three forms of bone damage in autoimmune arthritis: joint erosion, periarticular osteopenia, and systemic bone loss. Inflamm Regen 43:44. https:\/\/doi.org\/10.1186\/s41232-023-00293-3","journal-title":"Inflamm Regen"},{"key":"1410_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.829862","author":"J Li","year":"2022","unstructured":"Li J, Liang J, Wu L et al (2022) CYT387, a JAK-specific inhibitor impedes osteoclast activity and oophorectomy-induced osteoporosis via modulating RANKL and ROS signaling pathways. Front Pharmacol. https:\/\/doi.org\/10.3389\/fphar.2022.829862","journal-title":"Front Pharmacol"},{"key":"1410_CR13","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/nm.4385","volume":"23","author":"JN Farr","year":"2017","unstructured":"Farr JN, Xu M, Weivoda MM et al (2017) Targeting cellular senescence prevents age-related bone loss in mice. Nat Med 23:1072\u20131079. https:\/\/doi.org\/10.1038\/nm.4385","journal-title":"Nat Med"},{"key":"1410_CR14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181126","volume":"12","author":"K Murakami","year":"2017","unstructured":"Murakami K, Kobayashi Y, Uehara S et al (2017) A Jak1\/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. PLoS ONE 12:e0181126. https:\/\/doi.org\/10.1371\/journal.pone.0181126","journal-title":"PLoS ONE"},{"key":"1410_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.intimp.2018.03.021","volume":"58","author":"C Li","year":"2018","unstructured":"Li C, Xu L, Jian L et al (2018) Stattic inhibits RANKL-mediated osteoclastogenesis by suppressing activation of STAT3 and NF-\u03baB pathways. Int Immunopharmacol 58:136\u2013144. https:\/\/doi.org\/10.1016\/j.intimp.2018.03.021","journal-title":"Int Immunopharmacol"},{"key":"1410_CR16","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1001\/jama.2019.9055","volume":"322","author":"MC Genovese","year":"2019","unstructured":"Genovese MC, Kalunian K, Gottenberg J-E et al (2019) Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy. JAMA 322:315. https:\/\/doi.org\/10.1001\/jama.2019.9055","journal-title":"JAMA"},{"key":"1410_CR17","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1056\/NEJMoa2008250","volume":"383","author":"A Rubbert-Roth","year":"2020","unstructured":"Rubbert-Roth A, Enejosa J, Pangan AL et al (2020) Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med 383:1511\u20131521. https:\/\/doi.org\/10.1056\/NEJMoa2008250","journal-title":"N Engl J Med"},{"key":"1410_CR18","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMoa1310476","volume":"370","author":"EB Lee","year":"2014","unstructured":"Lee EB, Fleischmann R, Hall S et al (2014) Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 370:2377\u20132386. https:\/\/doi.org\/10.1056\/NEJMoa1310476","journal-title":"N Engl J Med"},{"key":"1410_CR19","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1056\/NEJMoa1608345","volume":"376","author":"PC Taylor","year":"2017","unstructured":"Taylor PC, Keystone EC, van der Heijde D et al (2017) Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 376:652\u2013662. https:\/\/doi.org\/10.1056\/NEJMoa1608345","journal-title":"N Engl J Med"},{"key":"1410_CR20","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1093\/rheumatology\/kes279","volume":"51","author":"J Kay","year":"2012","unstructured":"Kay J, Upchurch KS (2012) ACR\/EULAR 2010 rheumatoid arthritis classification criteria. Rheumatology 51:5\u20139. https:\/\/doi.org\/10.1093\/rheumatology\/kes279","journal-title":"Rheumatology"},{"key":"1410_CR21","doi-asserted-by":"publisher","unstructured":"(1993) Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 94:646\u2013650. https:\/\/doi.org\/10.1016\/0002-9343(93)90218-E","DOI":"10.1016\/0002-9343(93)90218-E"},{"key":"1410_CR22","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20621","author":"JK Anderson","year":"2011","unstructured":"Anderson JK, Zimmerman L, Caplan L, Michaud K (2011) Measures of rheumatoid arthritis disease activity: Patient (PtGA) and Provider (PrGA) Global Assessment of Disease Activity, Disease Activity Score (DAS) and Disease Activity Score With 28\u2010Joint Counts (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), Patient Activity Score (PAS) and Patient Activity Score\u2010II (PASII), Routine Assessment of Patient Index Data (RAPID), Rheumatoid Arthritis Disease Activity Index (RADAI) and Rheumatoid Arthritis. Arthritis Care Res (Hoboken). https:\/\/doi.org\/10.1002\/acr.20621","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"1410_CR23","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s00198-003-1525-x","volume":"15","author":"S Cvijeti\u0107","year":"2004","unstructured":"Cvijeti\u0107 S, Kor\u0161i\u0107 M (2004) Apparent bone mineral density estimated from DXA in healthy men and women. Osteoporos Int 15:295\u2013300. https:\/\/doi.org\/10.1007\/s00198-003-1525-x","journal-title":"Osteoporos Int"},{"key":"1410_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.867610","author":"H Huang","year":"2022","unstructured":"Huang H, Wang Y, Xie W et al (2022) Impact of treat-to-target therapy on bone mineral density loss in patients with rheumatoid arthritis: a prospective cohort study. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2022.867610","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1410_CR25","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1093\/jbmr\/zjae119","volume":"39","author":"F Cosman","year":"2024","unstructured":"Cosman F, Lewiecki EM, Eastell R et al (2024) Goal-directed osteoporosis treatment: ASBMR\/BHOF task force position statement 2024. J Bone Miner Res 39:1393\u20131405. https:\/\/doi.org\/10.1093\/jbmr\/zjae119","journal-title":"J Bone Miner Res"},{"key":"1410_CR26","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1359\/jbmr.1998.13.1.122","volume":"13","author":"TM Link","year":"1998","unstructured":"Link TM, Majumdar S, Lin JC et al (1998) A comparative study of trabecular bone properties in the spine and femur using high resolution MRI and CT. J Bone Miner Res 13:122\u2013132. https:\/\/doi.org\/10.1359\/jbmr.1998.13.1.122","journal-title":"J Bone Miner Res"},{"key":"1410_CR27","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1002\/art.42617","volume":"75","author":"D Simon","year":"2023","unstructured":"Simon D, Minopoulou I, Kemenes S et al (2023) Baricitinib improves bone properties and biomechanics in patients with rheumatoid arthritis: results of the prospective interventional <scp>BARE BONE<\/scp> trial. Arthritis Rheumatol 75:1923\u20131934. https:\/\/doi.org\/10.1002\/art.42617","journal-title":"Arthritis Rheumatol"},{"key":"1410_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/s41927-024-00414-6","volume":"8","author":"G Adami","year":"2024","unstructured":"Adami G, Orsolini G, Rossini M et al (2024) Effects of tofacitinib on bone turnover markers and bone modulators in patients with rheumatoid arthritis. BMC Rheumatol 8:40. https:\/\/doi.org\/10.1186\/s41927-024-00414-6","journal-title":"BMC Rheumatol"},{"key":"1410_CR29","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00198-021-05871-0","volume":"32","author":"A Hamar","year":"2021","unstructured":"Hamar A, Szekanecz Z, Pusztai A et al (2021) Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis. Osteoporos Int 32:1621\u20131629. https:\/\/doi.org\/10.1007\/s00198-021-05871-0","journal-title":"Osteoporos Int"},{"key":"1410_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41584-024-01120-w","volume":"20","author":"F Buttgereit","year":"2024","unstructured":"Buttgereit F, Palmowski A, Bond M et al (2024) Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases. Nat Rev Rheumatol 20:417\u2013431. https:\/\/doi.org\/10.1038\/s41584-024-01120-w","journal-title":"Nat Rev Rheumatol"},{"key":"1410_CR31","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1038\/s41591-024-03096-2","volume":"30","author":"JN Farr","year":"2024","unstructured":"Farr JN, Atkinson EJ, Achenbach SJ et al (2024) Effects of intermittent senolytic therapy on bone metabolism in postmenopausal women: a phase 2 randomized controlled trial. Nat Med 30:2605\u20132612. https:\/\/doi.org\/10.1038\/s41591-024-03096-2","journal-title":"Nat Med"},{"key":"1410_CR32","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s00393-016-0083-5","volume":"75","author":"B Obermayer-Pietsch","year":"2016","unstructured":"Obermayer-Pietsch B, Schwetz V (2016) Biochemische Marker des Knochenstoffwechsels und ihre Bedeutung. Z Rheumatol 75:451\u2013458. https:\/\/doi.org\/10.1007\/s00393-016-0083-5","journal-title":"Z Rheumatol"},{"key":"1410_CR33","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3343\/alm.2012.32.1.23","volume":"32","author":"S Atalay","year":"2012","unstructured":"Atalay S, Elci A, Kayadibi H et al (2012) Diagnostic utility of osteocalcin, undercarboxylated osteocalcin, and alkaline phosphatase for osteoporosis in premenopausal and postmenopausal women. Ann Lab Med 32:23\u201330. https:\/\/doi.org\/10.3343\/alm.2012.32.1.23","journal-title":"Ann Lab Med"},{"key":"1410_CR34","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40520-014-0296-x","volume":"27","author":"K Mukaiyama","year":"2015","unstructured":"Mukaiyama K, Kamimura M, Uchiyama S et al (2015) Elevation of serum alkaline phosphatase (ALP) level in postmenopausal women is caused by high bone turnover. Aging Clin Exp Res 27:413\u2013418. https:\/\/doi.org\/10.1007\/s40520-014-0296-x","journal-title":"Aging Clin Exp Res"},{"key":"1410_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/484280","volume":"2014","author":"P Fardellone","year":"2014","unstructured":"Fardellone P, S\u00e9journ\u00e9 A, Paccou J, Go\u00ebb V (2014) Bone remodelling markers in rheumatoid arthritis. Mediators Inflamm 2014:1\u20135. https:\/\/doi.org\/10.1155\/2014\/484280","journal-title":"Mediators Inflamm"},{"key":"1410_CR36","first-page":"241","volume":"23","author":"C Beyeler","year":"1996","unstructured":"Beyeler C, Banks R, Thompson D et al (1996) Bone alkaline phosphatase in rheumatoid arthritis: a longitudinal study. J Rheumatol 23:241\u2013244","journal-title":"J Rheumatol"},{"key":"1410_CR37","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.3899\/jrheum.20018538","volume":"47","author":"H Vergneault","year":"2020","unstructured":"Vergneault H, Vandebeuque E, Codullo V et al (2020) Disease activity score in 28 joints using GGT permits a dual evaluation of joint activity and cardiovascular risk. J Rheumatol 47:1738\u20131745. https:\/\/doi.org\/10.3899\/jrheum.20018538","journal-title":"J Rheumatol"},{"key":"1410_CR38","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR et al (2022) Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med 386:316\u2013326. https:\/\/doi.org\/10.1056\/NEJMoa2109927","journal-title":"N Engl J Med"},{"key":"1410_CR39","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","volume":"80","author":"G Nagy","year":"2021","unstructured":"Nagy G, Roodenrijs NM, Welsing PM et al (2021) EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis 80:31\u201335. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217344","journal-title":"Ann Rheum Dis"},{"key":"1410_CR40","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13075-022-02744-7","volume":"24","author":"S Ochi","year":"2022","unstructured":"Ochi S, Sonomoto K, Nakayamada S, Tanaka Y (2022) Preferable outcome of Janus kinase inhibitors for a group of difficult-to-treat rheumatoid arthritis patients: from the FIRST Registry. Arthritis Res Ther 24:61. https:\/\/doi.org\/10.1186\/s13075-022-02744-7","journal-title":"Arthritis Res Ther"},{"key":"1410_CR41","doi-asserted-by":"publisher","first-page":"2418","DOI":"10.1093\/rheumatology\/keae265","volume":"63","author":"R Watanabe","year":"2024","unstructured":"Watanabe R, Ebina K, Gon T et al (2024) Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study. Rheumatology 63:2418\u20132426. https:\/\/doi.org\/10.1093\/rheumatology\/keae265","journal-title":"Rheumatology"}],"updated-by":[{"DOI":"10.1007\/s00223-025-01451-0","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T00:00:00Z","timestamp":1764892800000}}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01410-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-025-01410-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-025-01410-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,26]],"date-time":"2025-12-26T13:21:09Z","timestamp":1766755269000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-025-01410-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1410"],"URL":"https:\/\/doi.org\/10.1007\/s00223-025-01410-9","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Retrospective open access order has been processed.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2025","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00223-025-01451-0","URL":"https:\/\/doi.org\/10.1007\/s00223-025-01451-0","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UML: Consultant for Lilly, PK: Consultant for Lilly. The others authors have no relevant financial or non-financial interests to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of Justus Liebig University Giessen (04.10.2018; AZ 149\/18).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed Consent"}}],"article-number":"101"}}